Literature DB >> 23174993

Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

Nisanne S Ghonem, James L Boyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23174993      PMCID： PMC4048949          DOI： 10.1002/hep.26155

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  26 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Authors:  Lucy J Walker; Julia Newton; David E J Jones; Margaret F Bassendine
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

3.  The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.

Authors:  S A Jones; L B Moore; J L Shenk; G B Wisely; G A Hamilton; D D McKee; N C Tomkinson; E L LeCluyse; M H Lambert; T M Willson; S A Kliewer; J T Moore
Journal:  Mol Endocrinol       Date:  2000-01

4.  Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.

Authors:  Núria Roglans; Manuel Vázquez-Carrera; Marta Alegret; Ferran Novell; Daniel Zambón; Emilio Ros; Juan C Laguna; Rosa M Sánchez
Journal:  Eur J Clin Pharmacol       Date:  2003-12-18       Impact factor: 2.953

5.  The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities.

Authors:  A P Day; M D Feher; R Chopra; P D Mayne
Journal:  Metabolism       Date:  1993-07       Impact factor: 8.694

6.  Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis.

Authors:  Hironori Nagasaka; Tohru Yorifuji; Kenichi Hirano; Akemi Ota; Yumiko Toyama-Nakagawa; Tomozumi Takatani; Hirokazu Tsukahara; Kunihiko Kobayashi; Masaki Takayanagi; Yukihiro Inomata; Shinji Uemoto; Takashi Miida
Journal:  Metabolism       Date:  2009-01       Impact factor: 8.694

7.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

8.  Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice.

Authors:  Takero Nakajima; Naoki Tanaka; Eiko Sugiyama; Yuji Kamijo; Atsushi Hara; Rui Hu; Gang Li; Yufeng Li; Kozo Nakamura; Frank J Gonzalez; Toshifumi Aoyama
Journal:  Biochem Pharmacol       Date:  2008-04-08       Impact factor: 5.858

Review 9.  Lipid-activated transcription factors control bile acid glucuronidation.

Authors:  Olivier Barbier; Jocelyn Trottier; Jenny Kaeding; Patrick Caron; Mélanie Verreault
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

10.  Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Authors:  Kazufumi Dohmen; Toshihiko Mizuta; Makoto Nakamuta; Naoya Shimohashi; Hiromi Ishibashi; Kyosuke Yamamoto
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742
View more
  14 in total

1.  Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.

Authors:  Nisanne S Ghonem; Meenakshisundaram Ananthanarayanan; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

2.  Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.

Authors:  Qi Zhao; Ting Zhang; Xue-Rong Xiao; Jian-Feng Huang; Yan Wang; Frank J Gonzalez; Fei Li
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

Review 3.  Advances in pharmacotherapy for primary biliary cirrhosis.

Authors:  Hani S Mousa; Ana Lleo; Pietro Invernizzi; Christopher L Bowlus; Merril Eric Gershwin
Journal:  Expert Opin Pharmacother       Date:  2014-12-29       Impact factor: 3.889

Review 4.  Fibrates and cholestasis.

Authors:  Nisanne S Ghonem; David N Assis; James L Boyer
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 5.  A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.

Authors:  Vinod S Hegade; Ruth Bolier; Ronald Pj Oude Elferink; Ulrich Beuers; Stuart Kendrick; David Ej Jones
Journal:  Frontline Gastroenterol       Date:  2015-08-26

Review 6.  Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.

Authors:  Yan Zhang; Sainan Li; Lei He; Fan Wang; Kan Chen; Jingjing Li; Tong Liu; Yuanyuan Zheng; Jianrong Wang; Wenxia Lu; Yuqing Zhou; Qin Yin; Yujing Xia; Yingqun Zhou; Jie Lu; Chuanyong Guo
Journal:  Drug Des Devel Ther       Date:  2015-05-25       Impact factor: 4.162

Review 7.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

Review 8.  Update on pharmacotherapies for cholestatic liver disease.

Authors:  Ahmad H Ali; James H Tabibian; Keith D Lindor
Journal:  Hepatol Commun       Date:  2016-12-21

9.  Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.

Authors:  Nisanne S Ghonem; Adam M Auclair; Christopher L Hemme; Gina M Gallucci; Randolph de la Rosa Rodriguez; James L Boyer; David N Assis
Journal:  Clin Pharmacol Ther       Date:  2020-07-17       Impact factor: 6.875

10.  PPARα activation protects against cholestatic liver injury.

Authors:  Qi Zhao; Rui Yang; Jing Wang; Dan-Dan Hu; Fei Li
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.